Chemistry:Ravidasvir
Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.[1]
It is on the World Health Organization's List of Essential Medicines.[2]
On December 11, 2024[3] it was approved in Russia under the trade name Konesko for the treatment of chronic hepatitis C in adult patients (only in combination with sofosbuvir). In the pivotal clinical trial STORM-C-1, the majority of patients were infected with HCV genotypes 1 or 3. Data from this study in patients with HCV genotypes 2 and 6 are limited, and data on patients with genotypes 4 or 5 are not available.[4]
Preliminary clinical trial results were announced in Nov 2015.[5] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.[6] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.[7][8]
References
- ↑ Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
- ↑ The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.
- ↑ "Unified registry of apruval drugs EAEU" (in Ru). https://pharma.eaeunion.org/pharma/registers/26/ru/register/registered-medicinal-products/65cf1c5c30dcf8482095ce7e.
- ↑ "Konesko (ravidasvir) Film-coated Tablets. Full Prescribing Information" (in ru). HTC «Chemrar». https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1a0127c0-603e-4716-9e86-d737147373b2.
- ↑ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. November 24, 2015. https://www.hepmag.com/article/PYRAMID-Sovaldi-ravidasvir-28085-1528583872.
- ↑ "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian. 13 April 2018. https://www.theguardian.com/science/2018/apr/12/non-profits-300-hepatitis-c-cure-as-effective-as-84000-alternative.
- ↑ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia". https://www.npra.gov.my/easyarticles/images/users/1047/Produk-yang-diluluskan-dalam-DCA-358-4-Jun-2021.pdf.
- ↑ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi" (in en-GB). 2021-06-14. https://dndi.org/press-releases/2021/first-hepatitis-c-treatment-developed-through-south-south-cooperation-registered-in-malaysia/.
 |  |
